# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Ashish Sabadra downgrades Cintas (NASDAQ:CTAS) from Outperform to Sector Perform and announces $725 pric...
Goldman Sachs recommends trading options for SBUX, CMG, WFC, and CTAS ahead of Q2 earnings. July preannouncements may affect TM...
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:NXGL), a leading provider of medical and over-the-counter (OTC...